NCT05940870View on ClinicalTrials.gov

A Prospective Post-marketing Observational Study Assessing the Safety and Efficacy of Nerivio for Migraine Prevention.

CompletedOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

July 3, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

August 1, 2024

Conditions
Migraine
Interventions
DEVICE

Nerivio

Patients with migraine who received the Nerivio device for migraine prevention therapy

Trial Locations (1)

08807

Theranica Inc USA, Bridgewater

Sponsors

Lead Sponsor

Theranica
All Listed Sponsors
lead

Theranica

INDUSTRY

NCT05940870 - A Prospective Post-marketing Observational Study Assessing the Safety and Efficacy of Nerivio for Migraine Prevention. | Biotech Hunter | Biotech Hunter